Leo Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

LEO Pharma is a long-established, private Danish pharmaceutical company with a singular focus on medical dermatology. The company is in a strong commercial phase, reporting a third consecutive year of double-digit revenue growth in 2025, a return to profitability, and positive free cash flow. Its strategy centers on advancing its pipeline in underserved dermatological areas, supporting external research through its Investigator Initiated Studies program, and building alliances to shape the future of skin disease treatment.

Dermatology

Technology Platform

Over 115 years of integrated dermatology drug development expertise across small molecules, biologics, and antibodies, supplemented by an open innovation ecosystem and a strategic Investigator Initiated Studies (IIS) program to fuel external research.

Opportunities

The large and growing global medical dermatology market offers significant opportunity, particularly in underserved disease areas.

Deepening real-world evidence and optimizing use of existing therapies like tralokinumab can drive further market penetration and patient benefit.

Strategic partnerships and external innovation through the IIS program can accelerate pipeline development and broaden the scientific reach.

Risk Factors

Intense competition in the dermatology therapeutic area from large pharma and biotech firms poses a constant threat to market share and pricing.

Revenue concentration on key products like tralokinumab creates dependency risk.

Global regulatory, pricing, and reimbursement challenges persist as significant hurdles for commercial success.

Competitive Landscape

LEO Pharma competes in the dynamic and crowded medical dermatology market. Key competitors include global pharmaceutical giants (e.g., AbbVie, Johnson & Johnson, Pfizer, Novartis) with major dermatology assets, as well as specialized biotech companies. Competition revolves around drug efficacy, safety, convenience, payer coverage, and real-world evidence generation.

More companies in Small Molecule Drugs →More companies in Denmark →